Affilogic is a private biotech company specialized in discovering and developing Nanofitins® through early-stage collaborations with worldwide industry leaders in the pharmaceutical sector.

These affinity proteins can be designed as targeted inhibitors, or as vectors for specific addressing of cells and tissues. Affilogic follows the science to any therapeutic area as long as an innovative Nanofitin-based biotherapy can make a difference to meet patients’ needs. Usual systemic routes can be travelled by Nanofitins®, but their intrinsic properties make them amenable to other routes, such as oral route and pulmonary delivery.

To learn more about the use of Nanofitins® as affinity ligands for the purification of biologics, you can visit the dedicated Affichrom’ website.

Affilogic wants to hear from you!

Affilogic to engage in a new project

Affilogic to engage in a new project

Affilogic announced that it engaged in a new project with the aim to target global health pathogens in lower middle income countries.

See the news here

BIO EUROPE SPRING 2023

BIO EUROPE SPRING 2023

Meet us at BIO EUROPE SPRING 2023 in Basel – Switzerland
Mar 20-22, 2023

Visit the event website

Technology

Your Nanofitins®

Our platforms